Equine Veterinary Journal (EQUINE VET J)

Publisher: British Equine Veterinary Association, Wiley

Journal description

This unrivalled international scientific journal was first published in 1968 when there were four issues each year. It now appears bi-monthly with around 88 pages per issue containing articles with original and potentially important findings. Contributions are received from sources worldwide, including North America, Europe and Australia. EVJ has also produced a number of Special Issues, which generally appear as an additional 7th issue devoted to a specific topic, including Immunology, Colic, Evidence-Based Medicine and Laminitis. These extra journals are distributed free to all subscribers, and are available to purchase from the EVJ Online Bookshop. All papers published in the journal are subjected to peer review and once articles have been accepted for publication they should appear in the journal within six to eight months. They present new developments in research being carried out by universities, veterinary schools and institutes devoted to equine and/or comparative physiology, pathology, medicine or surgery and from workers in practice. The journal strives to publish clinically orientated work and categorises articles into General Articles, Clinical Evidence Articles, Short Communications, Case Reports and Review Articles. General Articles are often accompanied by an Editorial Leader which gives the reader a further insight into a particular topic and provides further reference information. The Clinical Evidence category was introduced in 2003, for articles in which the objective is to answer questions of clinical importance in a controlled manner based on data obtainable in practice.

Current impact factor: 2.37

Impact Factor Rankings

2016 Impact Factor Available summer 2017
2014 / 2015 Impact Factor 2.374
2013 Impact Factor 2.369
2012 Impact Factor 2.286
2011 Impact Factor 1.456
2010 Impact Factor 1.799
2009 Impact Factor 1.837
2008 Impact Factor 2.08
2007 Impact Factor 1.607
2006 Impact Factor 1.73
2005 Impact Factor 1.317
2004 Impact Factor 1.44
2003 Impact Factor 1.496
2002 Impact Factor 1.256
2001 Impact Factor 1.816
2000 Impact Factor 1.479
1999 Impact Factor 1.411
1998 Impact Factor 1.329
1997 Impact Factor 1.58

Impact factor over time

Impact factor

Additional details

5-year impact 2.20
Cited half-life >10.0
Immediacy index 0.88
Eigenfactor 0.01
Article influence 0.51
Website Equine Veterinary Journal website
ISSN 2042-3306
OCLC 225017606
Material type Periodical
Document type Journal / Magazine / Newspaper

Publisher details


  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • Some journals have separate policies, please check with each journal directly
    • On author's personal website, institutional repositories, arXiv, AgEcon, PhilPapers, PubMed Central, RePEc or Social Science Research Network
    • Author's pre-print may not be updated with Publisher's Version/PDF
    • Author's pre-print must acknowledge acceptance for publication
    • Non-Commercial
    • Publisher's version/PDF cannot be used
    • Publisher source must be acknowledged with citation
    • Must link to publisher version with set statement (see policy)
    • If OnlineOpen is available, BBSRC, EPSRC, MRC, NERC and STFC authors, may self-archive after 12 months
    • If OnlineOpen is available, AHRC and ESRC authors, may self-archive after 24 months
    • Publisher last contacted on 07/08/2014
    • This policy is an exception to the default policies of 'Wiley'
  • Classification

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: There is limited information on clinical use of the new injectable anaesthetic agent alfaxalone in Thoroughbred horses. To compare anaesthetic induction and recovery characteristics and cardiopulmonary responses between alfaxalone, ketamine and thiopental in Thoroughbred horses premedicated with medetomidine and midazolam. Randomised blinded experimental cross-over study. Six Thoroughbred horses were anaesthetised 3 times with alfaxalone 1 mg/kg bwt, ketamine 2.5 mg/kg bwt or thiopental 4 mg/kg bwt after premedication with medetomidine 6 μg/kg bwt and midazolam 20 μg/kg bwt. Qualities of anaesthetic induction and recovery were scored on a scale of 1 (poor) to 5 (excellent). Induction time and recovery time were recorded. Cardiopulmonary values (heart rate, respiratory rate, arterial blood pressures, and arterial blood gases) were recorded throughout anaesthesia. Data were analysed with nonparametric methods. The anaesthetic induction (P = 0.2) and recovery (P = 0.1) quality scores (median, range) were not different amongst protocols and were 4.0, 3–5; 5.0, 4–5; 4.5, 3–5; and 4.5, 3–5; 3.5, 2–5; 4.0, 2–5 for alfaxalone, ketamine and thiopental, respectively. Induction time for ketamine (67, 53–89 s) was significantly longer than that for alfaxalone (49, 40–51 s, P = 0.01) and thiopental (48, 43–50 s, P = 0.01). Time to standing for alfaxalone (44, 40–63 min, P = 0.01) and thiopental (39, 30–58 min, P = 0.01) was significantly longer than that for ketamine (25, 18–26 min). Cardiovascular values were maintained within the clinically acceptable level throughout anaesthesia. Respiratory rate significantly decreased during anaesthesia for all 3 drugs; however, spontaneous breathing did not disappear, and PaCO2 values were maintained at approximately 50 mmHg. All 3 drugs showed similar effects in relation to anaesthetic induction and recovery qualities and cardiopulmonary responses. However, alfaxalone and thiopental prolonged recovery time compared with ketamine.
    No preview · Article · Feb 2016 · Equine Veterinary Journal
  • Source

    Preview · Article · Jan 2016 · Equine Veterinary Journal

  • No preview · Article · Jan 2016 · Equine Veterinary Journal

  • No preview · Article · Jan 2016 · Equine Veterinary Journal
  • [Show abstract] [Hide abstract]
    ABSTRACT: Reasons for performing study: While advanced stages of ascending placentitis can be diagnosed by transrectal ultrasonography and clinical signs, early stages can be missed. Thus, additional tools could enhance assessment of placental health. Objectives: To characterise peripheral dehydroepiandrosterone sulphate (DHEA-S) and testosterone concentrations in mares carrying normal pregnancies (Study I) and to compare plasma concentrations of DHEA-S, testosterone, oestradiol 17-β (oestradiol), and oestrone sulphate (OES) in mares with or without placentitis (Study II). Study design: Longitudinal cohort study of healthy mares (Study I) and controlled experiment (Study II) METHODS: In study I, mares had serum samples collected from 100d of gestation to term. In study II, pregnant mares (260-280d of gestation) were assigned to a control group or to a group with placentitis. Placentitis was induced via intracervical inoculation of Streptococcus equi ssp zooepidemicus. Blood was collected at inoculation/commencement for control mares (day = 0) and daily for 12 days post-inoculation (DPI) or until abortion. Steroid concentrations were determined by immunoassays. Concentrations of steroids in study II were also evaluated relative to days from abortion (DFA, -8 days to 0). Results: In study I, DHEA-S peaked by 180d of gestation, while testosterone concentrations were progressively increased from Days 100 to 180 with a plateau until ~240d and a progressive decline until 290d of gestation. In study II, concentrations of DHEA-S and testosterone were not significantly different between groups. There were significant effects of time (oestradiol p = 0.0008, OES p = 0.01) and time-by-group interactions (oestradiol p<0.001, OES p<0.0001) for oestrogen concentrations. For mares with experimental placentitis, concentrations of oestradiol were significantly reduced at -6, -2, -1 and 0 DFA, while OES concentrations were significantly reduced on the day before abortion (0 DFA). Conclusions: Testosterone and DHEA-S were increased and varied through pregnancy. Oestrogens but not androgens decreased significantly in mares with experimentally induced ascending placentitis. This article is protected by copyright. All rights reserved.
    No preview · Article · Jan 2016 · Equine Veterinary Journal
  • [Show abstract] [Hide abstract]
    ABSTRACT: Reasons for performing study: Right ventricular (RV) function is scarcely described in horses. Objectives: To establish reliable echocardiographic measurements of right heart size and function in horses. Study design: Descriptive study in healthy horses. Methods: Ten healthy untrained adult trotter horses underwent repeated echocardiography performed by 2 sonographers from right and left parasternal standard and nonstandard views. Nonstandard views included a right parasternal view focused on the right atrium, left parasternal long-axis pulmonary artery view, left parasternal long-axis view focused on the right ventricle including anatomical M-mode of tricuspid annular motion and left parasternal pulsed wave Doppler recording of pulmonary flow. During off-line analysis, 2 observers performed two-dimensional, M-mode, pulsed wave Doppler, tissue Doppler imaging (TDI) and two-dimensional speckle tracking (2DST) measurements of RV size and function. Acquisition and measurement variability were assessed by calculating coefficients of variation (CV) from one-way repeated measures analyses of variance. The degree of variability was classified as low (CV<15%), moderate (CV 15-25%) or high (CV>25%). Results: Most two-dimensional and M-mode measurements of RV, right atrial and pulmonary artery size showed low variability. The two-dimensional, M-mode and pulsed wave Doppler measurements of RV function showed a low to moderate variability. RV functional measurements by 2DST showed low variability, except for segmental strain rate. RV functional measurements by TDI showed a low to high variability, with a lower variability for timing than for peak measurements and a lower variability for velocity as compared to deformation measurements. Conclusions: Right heart size and function can be assessed with low variability in horses. This article is protected by copyright. All rights reserved.
    No preview · Article · Jan 2016 · Equine Veterinary Journal

  • No preview · Article · Jan 2016 · Equine Veterinary Journal

  • No preview · Article · Jan 2016 · Equine Veterinary Journal

  • No preview · Article · Jan 2016 · Equine Veterinary Journal

  • No preview · Article · Jan 2016 · Equine Veterinary Journal
  • [Show abstract] [Hide abstract]
    ABSTRACT: Reasons for performing study: It is accepted amongst equine practitioners that glucocorticoid treatment is a risk factor for the development of laminitis. However, there is little published evidence of a link between glucocorticoids and laminitis. Objectives: To determine whether horses receiving oral prednisolone are at increased risk of laminitis. Study design: Retrospective case-control study. Methods: Clinical records of horses registered with the ambulatory service at Liphook Equine Hospital between January 2001 and November 2014 were reviewed retrospectively to identify horses that had received treatment with oral prednisolone. For each treated horse, 2 time-matched controls that received veterinary attention but were not treated with prednisolone were selected. Incidence of laminitis was compared between the two groups and factors associated with laminitis were assessed using Cox regression analysis. Results: Of the 416 horses treated with prednisolone, 16 (3.9%) were diagnosed with laminitis subsequent to the initiation of prednisolone treatment; with an overall incidence of 2.60 (95% CI 1.49 - 4.22) cases per 100 horse-years at risk. Seven horses (1.7%) developed laminitis during the course of their treatment. Three (0.7%) of the horses treated with prednisolone were ultimately euthanased as a result of laminitis. Forty-six (5.7%), of the 814 time-matched control horses were diagnosed with laminitis during the study period with an overall incidence of 3.46 (95% CI 2.54 - 4.62) cases per 100 horse-years at risk. Twelve of these (1.5%) were euthanased as a result of laminitis. There were no significant differences in the overall laminitis incidence rate (p = 0.8), incidence rate during prednisolone treatment (p = 0.09) or probability of laminitis (p = 0.3) between the two groups. Mean survival time was greater in the prednisolone group than the control group. Equine metabolic syndrome and increasing age were associated with increased risk of laminitis. Conclusions: Administration of oral prednisolone did not increase the risk of laminitis. This article is protected by copyright. All rights reserved.
    No preview · Article · Dec 2015 · Equine Veterinary Journal
  • [Show abstract] [Hide abstract]
    ABSTRACT: Reasons for performing study: Objective criteria for predicting survival of chronic grass sickness cases are currently lacking. Objectives: To determine whether the rate and/or magnitude of bodyweight change during hospitalisation of chronic grass sickness cases can provide an objective predictor of survival to discharge from hospital. Clinicians' recorded indication(s) for euthanasia were also reviewed. Study design: Single centre retrospective observational study. Methods: Case records of all horses admitted for management of chronic grass sickness to The Dick Vet Equine Hospital between 1998 and 2013 were analysed. Signalment, survival to hospital discharge, indication(s) for euthanasia, disease duration at admission, and bodyweight changes during the hospitalisation period were analysed, and data for survivors and non-survivors compared. Percentage weight change was calculated for 7 day intervals up to 28 days (0-7, 7-14, 14-21, 21-28 days) and for entire periods from the first weight recorded (0-7, 0-14, 0-21, 0-28 days). These results were used to estimate survival probability conditional on weight change. Results: The study sample comprised 213 horses, with 114 survivors (53.5%) and 99 (46.5%) non-survivors. Compared with non-survivors, survivors had significantly lower median maximum bodyweight loss as a percentage of first weight (survivors 5.9%, interquartile range 1.8-13.5; non-survivors 12.7%, 6.4-17.3). Throughout all time periods analysed survivors had significantly lower median bodyweight loss than non-survivors, but no specific time period was more predictive of survival. Highest percentages of total bodyweight loss for individual horses were comparable for survivors (36%) and non-survivors (37%). Survival prediction curves reporting percentage survival rates for all time periods analysed provided data to aid prediction of chronic grass sickness survival. Conclusions: Overall non-survivors had greater bodyweight loss than survivors. Rapidity and magnitude of bodyweight loss were equally predictive of outcome. Percentage survival prediction curves provide objective data to aid discussion of prognosis, but greater predictive specificity with associated sensitivity is required for clinical decision making in individual cases. This article is protected by copyright. All rights reserved.
    No preview · Article · Dec 2015 · Equine Veterinary Journal
  • [Show abstract] [Hide abstract]
    ABSTRACT: Reasons for performing the study: The ante-mortem diagnosis of equine multinodular pulmonary fibrosis (EMPF) relies on histopathological results and PCR-positive EHV-5 testing of lung tissue. PCR detection of EHV-5 in bronchoalveolar lavage fluid (BALF) is commonly used to support a diagnosis of EMPF. However, the diagnostic power of EHV-5 testing on BALF and other biological samples such as blood and nasal secretions has yet to be shown to support a diagnosis of EMPF. Objectives: The objective this study was to determine the frequency of detection and the viral loads of EHV-5 by qPCR in blood, nasal secretions and BALF from horses confirmed with EMPF, healthy horses and horses with non-EMPF pulmonary diseases. Study design: Prospective study. Methods: The study population consisted of 70 adult horses divided into 4 groups based on a combination of clinical findings, cytology of BALF, imaging studies of the thoracic cavity and histopathology of pulmonary tissue: control group (n = 14), EMPF group (11), inflammatory airway disease (IAD) group (32), and non-EMPF interstitial lung disease group (13). For each horse, whole blood, nasal secretions and BALF were available for EHV-5 qPCR testing. Sensitivities, specificities, and their respective 95% confidence intervals were calculated for viral loads from blood, nasal secretions, and BALF. In addition, these measures were calculated for combined use of blood and nasal secretions. Results: The detection of EHV-5 in BALF was strongly associated with EMPF (sensitivity 91%, specificity 98.3%). Detection of EHV-5 in blood was, independent of the viral loads, strongly associated with EMPF with a sensitivity of 91% and specificity of 84.8%. The detection of EHV-5 in nasal secretions displayed the highest sensitivity (72.3%) and specificity (83%) at a level of >245,890 gB target genes/million cells to support a diagnosis of EMPF. Dually positive blood and nasal secretions at any viral loads in support of EMPF yielded a sensitivity and specificity of 90% and 89.8%, respectively. Conclusions: Although histopathological confirmation (lung biopsy) is considered a gold standard for EMPF diagnosis, results of qPCR testing of BALF or a combination of whole blood and nasal secretions should be regarded as clinically useful in support of this diagnosis. The latter testing may be relevant when dealing with horses in respiratory distress, for which invasive procedures such as BALF collection or lung biopsies may be detrimental to their health. This article is protected by copyright. All rights reserved.
    No preview · Article · Dec 2015 · Equine Veterinary Journal